Photodynamic Therapy of Psoriasis Using Photosensitizers of Vegetable Origin

Author(s): Marcos L. Bruschi*, Jéssica Bassi da Silva, Hélen C. Rosseto

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 20 , 2019


Become EABM
Become Reviewer
Call for Editor

Abstract:

Psoriasis is an immune-mediated, chronic and recurrent inflammatory skin disease, prevalent worldwide, and represents an important burden in life quality of patients. The most common clinical variant is termed as psoriasis vulgaris or plaque psoriasis, which with an individualized and carefully monitored therapy can decrease the patients’ morbidity and improving their life quality. The aim is to achieve disease control, minimize the adverse drug effects, and tailor the treatment to individual patient factors. Photodynamic therapy (PDT) is based on local or systemic administration of a non-toxic photosensitizer followed by irradiation with a particular wavelength to generate reactive oxygen species (ROS), mainly highly cytotoxic singlet oxygen (1O2). The generation of these species results in the attack to substrates involved in biological cycles causing necrosis and apoptosis of affected tissues. Photosensitizers are found in natural products and also obtained by partial syntheses from abundant natural starting compounds. They can be isolated at low cost and in large amounts from plants or algae. Therefore, this manuscript reviews the use of molecules from vegetal sources as photosensitizer agents for the PDT of psoriasis. Psoriasis pathogenesis, management and treatment were reviewed. PDT principles, fundamentals and utilization for the treatment of psoriasis were also discussed. Photosensitizers for PDT of psoriasis are also reviewed focusing on those from vegetal sources. Despite the PDT is utilized for the treatment of psoriasis, very little amount of photosensitizers from plant sources are utilized, such as chlorophyll derivatives and hypericin; however, other natural photosensitizers such as curcumin, could also be investigated. They could constitute a very important, safe and cheap alternative for the successful photodynamic treatment of psoriasis.

Keywords: Psoriasis, plant source, photo-activation, photosensitizer, skin, photodynamic therapy, topical application.

[1]
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
[http://dx.doi.org/10.1056/NEJMra0804595] [PMID: 19641206]
[2]
Higgins E Psoriasis. Medicine 2017; 45(6): 368-78.
[http://dx.doi.org/10.1016/j.mpmed.2017.03.010]
[3]
Smits T, Kleinpenning MM, van Erp PEJ, van de Kerkhof PC, Gerritsen MJ. A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis. Br J Dermatol 2006; 155(2): 429-36.
[http://dx.doi.org/10.1111/j.1365-2133.2006.07290.x] [PMID: 16882185]
[4]
Schadler ED, Ortel B, Mehlis SL. Biologics for the primary care physician: Review and treatment of psoriasis. Dis Mon 2019; 65(3): 51-90.
[http://dx.doi.org/10.1016/j.disamonth.2018.06.001] [PMID: 30037762]
[5]
Christophers E, Mrowietz U. Psoriasis In: Burgdorf W, Plewig G, Wolff HH, Landthaler M, Eds Braun-Falco’s Dermatology Berlin Heidelberg: Springer Verlag 2009; pp. 506-26.
[http://dx.doi.org/10.1007/978-3-540-29316-3_36]
[6]
Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63(1): 40-6.
[http://dx.doi.org/[https://doi.org/10.1016/j.jdermsci.2011.03.002] [PMID: 21543188]
[7]
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133(2): 377-85.
[http://dx.doi.org/10.1038/jid.2012.339] [PMID: 23014338]
[8]
Jain S. Dermatology: Illustrated Study Guide and Comprehensive Board Review. 2nd ed. Cham: Springer 2017.
[http://dx.doi.org/10.1007/978-3-319-47395-6]
[9]
Tandon YK, Yang MF, Baron ED. Role of photodynamic therapy in psoriasis: a brief review. Photodermatol Photoimmunol Photomed 2008; 24(5): 222-30.
[http://dx.doi.org/10.1111/j.1600-0781.2008.00376.x] [PMID: 18811862]
[10]
Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24(2)(Suppl. 2): 31-5.
[http://dx.doi.org/[https://doi.org/10.1111/j.1468-3083.2009.03565.x] [PMID: 20443998]
[11]
Weigle N, McBane S. Psoriasis. Am Fam Physician 2013; 87(9): 626-33.
[PMID: 23668525]
[12]
Lapolla W, Yentzer BA, Bagel J, Halvorson CR, Feldman SR. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol 2011; 64(5): 936-49.
[http://dx.doi.org/10.1016/j.jaad.2009.12.054] [PMID: 21429620]
[13]
Racz E, Prens EP. Phototherapy and photochemotherapy for psoriasis. Dermatol Clin 2015; 33(1): 79-89.
[http://dx.doi.org/10.1016/j.det.2014.09.007] [PMID: 25412785]
[14]
Bonnett R. Chemical aspects of photodynamic therapy. 1st ed. London: CRC Press 2000.
[http://dx.doi.org/10.1201/9781482296952]
[15]
Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci 2018; 33(1): 173-80.
[http://dx.doi.org/10.1007/s10103-017-2360-1] [PMID: 29067616]
[16]
Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001; 26(4): 343-50.
[http://dx.doi.org/10.1046/j.1365-2230.2001.00828.x] [PMID: 11422187]
[17]
Lerner AB, Denton CR, Fitzpatrick TB. Clinical and experimental studies with 8-methoxypsoralen in vitiligo. J Invest Dermatol 1953; 20(4): 299-314.
[http://dx.doi.org/10.1038/jid.1953.36] [PMID: 13052979]
[18]
Boiy A, Roelandts R, de Witte PAM. Photodynamic therapy using topically applied hypericin: comparative effect with methyl-aminolevulinic acid on UV induced skin tumours. J Photochem Photobiol B 2011; 102(2): 123-31.
[http://dx.doi.org/10.1016/j.jphotobiol.2010.09.012] [PMID: 21035351]
[19]
Choudhary S, Nouri K, Elsaie ML. Photodynamic therapy in dermatology: a review. Lasers Med Sci 2009; 24(6): 971-80.
[http://dx.doi.org/10.1007/s10103-009-0716-x] [PMID: 19653060]
[20]
Schäfer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 2007; 59(6): 427-43.
[http://dx.doi.org/10.1016/j.addr.2007.04.006] [PMID: 17544165]
[21]
Menon GK, Cleary GW, Lane ME. The structure and function of the stratum corneum. Int J Pharm 2012; 435(1): 3-9.
[http://dx.doi.org/10.1016/j.ijpharm.2012.06.005] [PMID: 22705878]
[22]
Haque T, Rahman KM, Thurston DE, Hadgraft J, Kane ME. Topical therapies for skin cancer and actinic keratosis. Eur J Pharm Sci 2015; 77: 279-89.
[http://dx.doi.org/10.1016/j.ejps.2015.06.013] [PMID: 26091570]
[23]
Benson HAE. Skin structure, function, and permeation In: Benson HAE, Watkinson AC, Eds Transdermal and topical drug delivery Hoboken: Wiley 2012; pp. 3-22.
[http://dx.doi.org/10.1002/9781118140505.ch1]
[24]
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370(9583): 263-71.
[http://dx.doi.org/10.1016/S0140-6736(07)61128-3] [PMID: 17658397]
[25]
Morici N, Ferri LA, Alicandro G, et al. Psoriasis and the risk of acute coronary syndrome in the elderly. Int J Cardiol 2018; 273: 44-6.
[http://dx.doi.org/10.1016/j.ijcard.2018.07.134] [PMID: 30064923]
[26]
Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life Ann Rheum Dis 2005 64)(Suppl. 2): 18-23.
[http://dx.doi.org/10.1136/ard.2004.033217] [PMID: 15708928]
[27]
Mrowietz U, Steinz K, Gerdes S. Psoriasis: to treat or to manage? Exp Dermatol 2014; 23(10): 705-9.
[http://dx.doi.org/10.1111/exd.12437] [PMID: 24815425]
[28]
Goldenberg G, Lanoue J, Dong J. New oral therapies for psoriasis: a comprehensive review. J Clin Aesthet Dermatol 2016; 9(8): 25-8.
[PMID: 27672415]
[29]
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61(3): 451-85.
[http://dx.doi.org/10.1016/j.jaad.2009.03.027] [PMID: 19493586]
[30]
Laws PM, Warren RB. Ustekinumab for the treatment of psoriasis. Expert Rev Clin Immunol 2011; 7(2): 155-64.
[http://dx.doi.org/10.1586/eci.11.4] [PMID: 21426253]
[31]
Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers Med Sci 2018; 33(1): 173-80.
[http://dx.doi.org/10.1007/s10103-017-2360-1] [PMID: 29067616]
[32]
Allison RR, Moghissi K. Photodynamic therapy (PDT): PDT mechanisms. Clin Endosc 2013; 46(1): 24-9.
[http://dx.doi.org/10.5946/ce.2013.46.1.24] [PMID: 23422955]
[33]
Villacorta RB, Roque KFJ, Tapang GA, Jacinto SD. Plant extracts as natural photosensitizers in photodynamic therapy: in vitro activity against human mammary adenocarcinoma MCF-7 cells. Asian Pac J Trop Biomed 2017; 7(4): 358-66.
[http://dx.doi.org/10.1016/j.apjtb.2017.01.025]
[34]
Fritsch C, Goerz G, Ruzicka T. Photodynamic therapy in dermatology. Arch Dermatol 1998; 134(2): 207-14.
[http://dx.doi.org/10.1001/archderm.134.2.207] [PMID: 9487213]
[35]
Machado AEH. Photodynamic therapy: principles, potential of application and perspectives. Quim Nova 2000; 23(2): 237-43.
[http://dx.doi.org/10.1590/S0100-40422000000200015]
[36]
Tomazini MV, Souza CS, Garcia SB, Tedesco AC. Topical photodynamic therapy with zinc phthalocyanine: evaluation of fluorescence intensity, skin absorption, skin histological and immunohistochemical changes in animal model. An Bras Dermatol 2007; 82(6): 535-41.
[http://dx.doi.org/10.1590/S0365-05962007000600006]
[37]
Perussi JR. Photodynamic inactivation of microorganisms. Quim Nova 2007; 30(4): 988-94.
[http://dx.doi.org/10.1590/S0100-40422007000400039]
[38]
Allison RR, Mota HC, Sibata CH. Clinical PD/PDT in North America: An historical review. Photodiagn Photodyn Ther 2004; 1(4): 263-77.
[http://dx.doi.org/10.1016/S1572-1000(04)00084-5] [PMID: 25048431]
[39]
Raab O. Über die Wirkung Fluoreszierender Stoffe auf Infusorien. Z Biol 1900; 39: 546-46.
[40]
Pathak MA, Fitzpatrick TB. The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. J Photochem Photobiol B 1992; 14(1-2): 3-22.
[http://dx.doi.org/10.1016/1011-1344(92)85080-E] [PMID: 1432383]
[41]
Craig RA, McCoy CP, Gorman SP, Jones DS. Photosensitisers - the progression from photodynamic therapy to anti-infective surfaces. Expert Opin Drug Deliv 2015; 12(1): 85-101.
[http://dx.doi.org/10.1517/17425247.2015.962512] [PMID: 25247277]
[42]
Baltazar LM, Ray A, Santos DA, Cisalpino OS, Firedman AJ, Nosanchuk JD. Antimicrobial photodynamic therapy: an effective alternative approach to control fungal infections. Front Microbiol 2015; 6: 1-11.
[http://dx.doi.org/10.3389/fmicb.2015.00202] [PMID: 25821448]
[43]
Daniell MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg 1991; 61(5): 340-8.
[http://dx.doi.org/10.1111/j.1445-2197.1991.tb00230.x] [PMID: 2025186]
[44]
Yoon I, Li JZ, Shim YK. Advance in photosensitizers and light delivery for photodynamic therapy. Clin Endosc 2013; 46(1): 7-23.
[http://dx.doi.org/10.5946/ce.2013.46.1.7] [PMID: 23423543]
[45]
Verma S, Watt GM, Mai Z, Hasan T. Strategies for enhanced photodynamic therapy effects. Photochem Photobiol 2007; 83(5): 996-1005.
[http://dx.doi.org/10.1111/j.1751-1097.2007.00166.x] [PMID: 17880492]
[46]
Wainwright M. Non-porphyrin photosensitizers in biomedicine. Chem Soc Rev 1996; 25: 351-9.
[http://dx.doi.org/10.1039/cs9962500351]
[47]
Jong WW, Tan PJ, Kamarulzaman FA, et al. Photodynamic activity of plant extracts from Sarawak, Borneo. Chem Biodivers 2013; 10(8): 1475-86.
[http://dx.doi.org/10.1002/cbdv.201200303] [PMID: 23939795]
[48]
Christiansen K, Bjerring P, Troilius A. 5-ALA for photodynamic photorejuvenation--optimization of treatment regime based on normal-skin fluorescence measurements. Lasers Surg Med 2007; 39(4): 302-10.
[http://dx.doi.org/10.1002/lsm.20488] [PMID: 17457834]
[49]
Borghi-Pangoni FB, Junqueira MV, de Souza Ferreira SB, et al. Preparation and characterization of bioadhesive system containing hypericin for local photodynamic therapy. Photodiagn Photodyn Ther 2017; 19: 284-97.
[http://dx.doi.org/10.1016/j.pdpdt.2017.06.016] [PMID: 28669792]
[50]
Borghi-Pangoni FB, Junqueira MV, de Souza Ferreira SB, et al. Screening and in vitro evaluation of mucoadhesive thermoresponsive system containing methylene blue for local photodynamic therapy of colorectal cancer. Pharm Res 2016; 33(3): 776-91.
[http://dx.doi.org/10.1007/s11095-015-1826-8] [PMID: 26553353]
[51]
Campanholi KDSS, Braga G, da Silva JB, et al. Biomedical platform development of a chlorophyll-based extract for topic photodynamic therapy: mechanical and spectroscopic properties. Langmuir 2018; 34(28): 8230-44.
[http://dx.doi.org/10.1021/acs.langmuir.8b00658] [PMID: 29933698]
[52]
Bastos MM, Boechat N, Gomes ATPC, Neves MGPMS, Cavaleiro JAS. The use of porphyrins in photodynamic therapy of cutaneous leishmaniasis. Rev Virtual Quim 2012; 4(3): 257-67.
[http://dx.doi.org/10.5935/1984-6835.20120021]
[53]
Choi YM, Adelzadeh L, Wu JJ. Photodynamic therapy for psoriasis. J Dermatolog Treat 2015; 26(3): 202-7.
[http://dx.doi.org/10.3109/09546634.2014.927816] [PMID: 24881473]
[54]
Boehncke W-H. Topical photodynamic therapy for psoriasis. Calzavara- Pinton P-G, Szeimies R-M, Ortel B, Eds. Photodynamic therapy and fluorescence diagnosis in dermatology. Amsterdam: Elsevier 2001; pp. 259-70.
[http://dx.doi.org/10.1016/S1568-461X(01)80120-4]
[55]
Wen X, Li Y, Hamblin MR. Photodynamic therapy in dermatology beyond non-melanoma cancer: An update. Photodiagn Photodyn Ther 2017; 19: 140-52.
[http://dx.doi.org/10.1016/j.pdpdt.2017.06.010] [PMID: 28647616]
[56]
Beattie PE, Dawe RS, Ferguson J, Ibbotson SH. Lack of efficacy and tolerability of topical PDT for psoriasis in comparison with narrowband UVB phototherapy. Clin Exp Dermatol 2004; 29(5): 560-2.
[http://dx.doi.org/10.1111/j.1365-2230.2004.01604.x] [PMID: 15347356]
[57]
Carrascosa JM, López-Estebaranz JL, Carretero G, et al. Narrowband UV-B, monochromatic excimer laser, and photodynamic therapy in psoriasis: a consensus statement of the Spanish Psoriasis Group. Actas Dermosifiliogr 2011; 102(3): 175-86.
[http://dx.doi.org/10.1016/S1578-2190(11)70782-X] [PMID: 21310368]
[58]
Fernández-Guarino M, García-Morales I, Harto A, Montull C, Pérez-García B, Jaén P. Photodynamic therapy: new indications. Actas Dermosifiliogr 2007; 98(6): 377-95.
[http://dx.doi.org/10.1016/S1578-2190(07)70471-7] [PMID: 17663928]
[59]
Oniszczuk A, Wojtunik-Kulesza KA, Oniszczuk T, Kasprzak K. The potential of photodynamic therapy (PDT)-Experimental investigations and clinical use. Biomed Pharmacother 2016; 83: 912-29.
[http://dx.doi.org/10.1016/j.biopha.2016.07.058] [PMID: 27522005]
[60]
Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother 2018; 106: 1098-107.
[http://dx.doi.org/10.1016/j.biopha.2018.07.049] [PMID: 30119176]
[61]
Miller JD, Baron ED, Scull H, et al. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. Toxicol Appl Pharmacol 2007; 224(3): 290-9.
[http://dx.doi.org/10.1016/j.taap.2007.01.025] [PMID: 17397888]
[62]
Salah M, Samy N, Fadel M. Methylene blue mediated photodynamic therapy for resistant plaque psoriasis. J Drugs Dermatol 2009; 8(1): 42-9.
[PMID: 19180895]
[63]
Semeraro P, Chimienti G, Altamura E, Fini P, Rizzi V, Cosma P. Chlorophyll a in cyclodextrin supramolecular complexes as a natural photosensitizer for photodynamic therapy (PDT) applications. Mater Sci Eng C 2018; 85: 47-56.
[http://dx.doi.org/10.1016/j.msec.2017.12.012] [PMID: 29407156]
[64]
Krasnovsky AA, Neverov KV, Egorov SY, Roeder B, Levald T. Photophysical studies of pheophorbide a and pheophytin a. Phosphorescence and photosensitized singlet oxygen luminescence. J Photochem Photobiol B 1990; 5(2): 245-54.
[http://dx.doi.org/10.1016/1011-1344(90)80009-M] [PMID: 2111399]
[65]
Ebermann R, Alth G, Kreitner M, Kubin A. Natural products derived from plants as potential drugs for the photodynamic destruction of tumor cells. J Photochem Photobiol B 1996; 36(2): 95-7.
[http://dx.doi.org/10.1016/S1011-1344(96)07353-8] [PMID: 9002245]
[66]
Ferruzzi MG, Blakeslee J. Digestion, absorption, and cancer preventative activity of dietary chlorophyll derivatives. Nutr Res 2007; 27(1): 1-12.
[http://dx.doi.org/10.1016/j.nutres.2006.12.003]
[67]
Brandis AS, Salomon Y, Scherz A. Chlorophyll Sensitizers in Photodynamic Therapy In: Grimm B, Porra RJ, Rüdiger W, Scheer H, Eds Chlorophylls and bacteriochlorophylls: Biochemistry Dordrecht: Springer 2006; pp. 461-83.
[http://dx.doi.org/10.1007/1-4020-4516-6_32]
[68]
Ulatowska-Jarża A, Zychowicz J, Hołowacz I, et al. Antimicrobial PDT with chlorophyll-derived photosensitizer and semiconductor laser. Med Laser Appl 2006; 21(3): 177-83.
[http://dx.doi.org/10.1016/j.mla.2006.05.003]
[69]
Gomaa I, Ali SE, El-Tayeb TA, Abdel-Kader MH. Chlorophyll derivative mediated PDT versus methotrexate: an in vitro study using MCF-7 cells. Photodiagn Photodyn Ther 2012; 9(4): 362-8.
[http://dx.doi.org/10.1016/j.pdpdt.2012.04.001] [PMID: 23200019]
[70]
Chu M, Li H, Wu Q, Wo F, Shi D. Pluronic-encapsulated natural chlorophyll nanocomposites for in vivo cancer imaging and photothermal/photodynamic therapies. Biomaterials 2014; 35(29): 8357-73.
[http://dx.doi.org/10.1016/j.biomaterials.2014.05.049] [PMID: 25002262]
[71]
Morlière P, Mazière JC, Santus R, et al. Tolyporphin: a natural product from cyanobacteria with potent photosensitizing activity against tumor cells in vitro and in vivo. Cancer Res 1998; 58(16): 3571-8.
[PMID: 9721863]
[72]
Gasparetto A, Lapinski TF, Zamuner SR, et al. Extracts from Alternanthera maritima as natural photosensitizers in photodynamic antimicrobial chemotherapy (PACT). J Photochem Photobiol B 2010; 99(1): 15-20.
[http://dx.doi.org/10.1016/j.jphotobiol.2010.01.009] [PMID: 20172737]
[73]
Andreazza NL, Caramano de Lourenço C, Hernandez-Tasco AJ, et al. Antimicrobial photodynamic effect of extracts and oxoaporphine alkaloid isomoschatoline from Guatteria blepharophylla. J Photochem Photobiol B 2016; 160: 154-62.
[http://dx.doi.org/10.1016/j.jphotobiol.2016.04.010] [PMID: 27107335]
[74]
Ormond AB, Freeman HS. Dye sensitizers for photodynamic therapy. Materials (Basel) 2013; 6(3): 817-40.
[http://dx.doi.org/10.3390/ma6030817] [PMID: 28809342]
[75]
Santezi C, Reina BD, Dovigo LN. Curcumin-mediated Photodynamic Therapy for the treatment of oral infections-A review. Photodiagn Photodyn Ther 2018; 21: 409-15.
[http://dx.doi.org/10.1016/j.pdpdt.2018.01.016] [PMID: 29378256]
[76]
Jain A, Doppalapudi S, Domb AJ, Khan W. Tacrolimus and curcumin co-loaded liposphere gel: Synergistic combination towards management of psoriasis. J Control Release 2016; 243: 132-45.
[http://dx.doi.org/10.1016/j.jconrel.2016.10.004] [PMID: 27725194]
[77]
Kang D, Li B, Luo L, et al. Curcumin shows excellent therapeutic effect on psoriasis in mouse model. Biochimie 2016; 123: 73-80.
[http://dx.doi.org/10.1016/j.biochi.2016.01.013] [PMID: 26826458]
[78]
Nardo VD, Gianfaldoni S, Tchernev G, et al. Use of Curcumin in Psoriasis. Open Access Maced J Med Sci 2018; 6(1): 218-20.
[http://dx.doi.org/10.3889/oamjms.2018.055] [PMID: 29484027]
[79]
Sun J, Zhao Y, Hu J. Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PLoS One 2013; 8(6)e67078
[http://dx.doi.org/10.1371/journal.pone.0067078] [PMID: 23825622]
[80]
Kamuhabwa AR, Roelandts R, de Witte PA. Skin photosensitization with topical hypericin in hairless mice. J Photochem Photobiol B 1999; 53(1-3): 110-4.
[http://dx.doi.org/10.1016/S1011-1344(99)00135-9] [PMID: 10672536]
[81]
Rook AH, Wood GS, Duvic M, Wonderheid EC, Tobia A, Cabana B. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol 2010; 63(6): 984-90.
[http://dx.doi.org/10.1016/j.jaad.2010.02.039] [PMID: 20889234]
[82]
Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Temoporfin-loaded invasomes: development, characterization and in vitro skin penetration studies. J Control Release 2008; 127(1): 59-69.
[http://dx.doi.org/10.1016/j.jconrel.2007.12.013] [PMID: 18281119]
[83]
Dragicevic-Curic N, Winter S, Krajisnik D, et al. Stability evaluation of temoporfin-loaded liposomal gels for topical application. J Liposome Res 2010; 20(1): 38-48.
[http://dx.doi.org/10.3109/08982100903030263] [PMID: 19558347]
[84]
Bissonnette R, Tremblay JF, Juzenas P, Boushira M, Lui H. Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques. J Invest Dermatol 2002; 119(1): 77-83.
[http://dx.doi.org/10.1046/j.1523-1747.2002.01827.x] [PMID: 12164928]
[85]
Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol 2002; 146(2): 178-88.
[http://dx.doi.org/10.1046/j.0007-0963.2001.04689.x] [PMID: 11903225]
[86]
Chiu H-Y, Chang W-L, Shiu M-N, et al. Psoriasis is associated with a greater risk for cardiovascular procedure and surgery in patients with hypertension: A nationwide cohort study. J Dermatol 2018; 45(12): 1381-8.
[http://dx.doi.org/10.1111/1346-8138.14654] [PMID: 30328149]
[87]
Robinson DJ, Collins P, Stringer MR, et al. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. Acta Derm Venereol 1999; 79(6): 451-5.
[http://dx.doi.org/10.1080/000155599750009898] [PMID: 10598759]
[88]
Collins P, Robinson DJ, Stringer MR, Stables GI, Sheehan-Dare RA. The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 1997; 137(5): 743-9.
[http://dx.doi.org/10.1111/j.1365-2133.1997.tb01111.x] [PMID: 9415234]
[89]
Doppalapudi S, Jain A, Chopra DK, Khan W. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis. Eur J Pharm Sci 2017; 96: 515-29.
[http://dx.doi.org/10.1016/j.ejps.2016.10.025]
[90]
Pramual S, Lirdprapamongkol K, Svasti J, et al. Polymer-lipid-PEG hybrid nanoparticles as photosensitizer carrier for photodynamic therapy. J Photochem Photobiol B 2017; 173: 12-22.
[http://dx.doi.org/10.1016/j.jphotobiol.2017.05.028] [PMID: 28554072]
[91]
Shadab MD, Haque S, Madheswaran T, et al. Lipid based nanocarriers system for topical delivery of photosensitizers. Drug Discov Today 2017; 22: 1274-83.
[http://dx.doi.org/10.1016/j.drudis.2017.04.010]
[92]
Chen J, Shao R, Zhang XD, Chen C. Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int J Nanomedicine 2013; 8: 2677-88.
[http://dx.doi.org/10.2147/IJN.S45429] [PMID: 23926430]
[93]
Monge-Fuentes V, Muehlmann LA, de Azevedo RB. Perspectives on the application of nanotechnology in photodynamic therapy for the treatment of melanoma. Nano Rev 2014; 5: 1-15.
[http://dx.doi.org/10.3402/nano.v5.24381] [PMID: 25317253]
[94]
Sun L, Liu Z, Wang L, et al. Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel. J Control Release 2017; 254: 44-54.
[http://dx.doi.org/10.1016/j.jconrel.2017.03.385] [PMID: 28344018]
[95]
Mezei M, Gulasekharam V. Liposomes-a selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci 1980; 26(18): 1473-7.
[http://dx.doi.org/10.1016/0024-3205(80)90268-4] [PMID: 6893068]
[96]
Pradhan M, Alexander A, Singh MR, et al. Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed Pharmacother 2018; 107: 447-63.
[http://dx.doi.org/10.1016/j.biopha.2018.07.156] [PMID: 30103117]
[97]
Jin Y, Zhang X, Zhang B, Kang H, Du L, Li M. Nanostructures of an amphiphilic zinc phthalocyanine polymer conjugate for photodynamic therapy of psoriasis. Colloids Surf B Biointerfaces 2015; 128: 405-9.
[http://dx.doi.org/10.1016/j.colsurfb.2015.02.038] [PMID: 25766924]
[98]
de Souza TD, Ziembowicz FI, Müller DF, et al. Evaluation of photodynamic activity, photostability and in vitro drug release of zinc phthalocyanine-loaded nanocapsules. Eur J Pharm Sci 2016; 83: 88-98.
[http://dx.doi.org/10.1016/j.ejps.2015.12.006] [PMID: 26678154]
[99]
Costa FA, Gerola AP, Pereira PCS, et al. Chlorophylls B formulated in nanostructured colloidal solutions: Interaction, spectroscopic, and photophysical studies. J Mol Liq 2019; 274: 393-401.
[http://dx.doi.org/10.1016/j.molliq.2018.10.143]
[100]
Ren J, Fang Z, Yao L, et al. A micelle-like structure of poloxamer-methotrexate conjugates as nanocarrier for methotrexate delivery. Int J Pharm 2015; 487(1-2): 177-86.
[http://dx.doi.org/10.1016/j.ijpharm.2015.04.014] [PMID: 25865570]
[101]
Pellosi DS, Estevão BM, Semensato J, et al. Photophysical properties and interactions of xanthene dyes in aqueous micelles. J Photochem Photobiol Chem 2012; 247: 8-15.
[http://dx.doi.org/10.1016/j.jphotochem.2012.07.009]
[102]
Junqueira MV, Borghi-Pangoni FB, Ferreira SBS, Rabello BR, Hioka N, Bruschi ML. Functional polymeric systems as delivery vehicles for methylene blue in photodynamic therapy. Langmuir 2016; 32(1): 19-27.
[http://dx.doi.org/10.1021/acs.langmuir.5b02039] [PMID: 26673856]
[103]
Junqueira MV, Borghi-Pangoni FB, Ferreira SBS, Bruschi ML. Evaluation of the methylene blue addition in binary polymeric systems composed by poloxamer 407 and Carbopol 934P using quality by design: rheological, textural, and mucoadhesive analysis. Drug Dev Ind Pharm 2016; 42(12): 2009-19.
[http://dx.doi.org/10.1080/03639045.2016.1188111] [PMID: 27161762]
[104]
Oliveira MB, da Silva JB, Montanha MC, Kimura E, Diniz A, Bruschi ML. Design and characterization of mucoadhesive gelatin-ethylcellulose microparticles for the delivery of curcumin to the bladder. Curr Drug Deliv 2018; 15(8): 1112-22.
[http://dx.doi.org/10.2174/1567201815666180503121043] [PMID: 29732969]
[105]
Feng J, Wu S, Wang H, et al. Improved bioavailability of curcumin in ovalbumin-dextran nanogels prepared by Maillard reaction. J Funct Foods 2016; 27: 55-68.
[http://dx.doi.org/10.1016/j.jff.2016.09.002]
[106]
Sarika PR, James NR. Anil kumar PR, Raj DK. Preparation, characterization and biological evaluation of curcumin loaded alginate aldehyde–gelatin nanogels. Mater Sci Eng C 2016; 68: 251-7.
[http://dx.doi.org/10.1016/j.msec.2016.05.046]
[107]
Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005; 104(6): 1322-31.
[http://dx.doi.org/10.1002/cncr.21300] [PMID: 16092118]
[108]
Fang M, Jin Y, Bao W, et al. In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. Int J Nanomedicine 2012; 7: 5395-404.
[http://dx.doi.org/10.2147/IJN.S36257] [PMID: 23091382]
[109]
Kang NW, Kim MH, Sohn SY, et al. Curcumin-loaded lipid-hybridized cellulose nanofiber film ameliorates imiquimod-induced psoriasis-like dermatitis in mice. Biomaterials 2018; 182: 245-58.
[http://dx.doi.org/10.1016/j.biomaterials.2018.08.030] [PMID: 30142524]
[110]
Kim JY, Kang HY, Lee ES, Kim YC. Topical 5-aminolaevulinic acid photodynamic therapy for intractable palmoplantar psoriasis. J Dermatol 2007; 34(1): 37-40.
[http://dx.doi.org/10.1111/j.1346-8138.2007.00213.x] [PMID: 17204099]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 20
Year: 2019
Published on: 18 September, 2019
Page: [2279 - 2291]
Pages: 13
DOI: 10.2174/1381612825666190618122024
Price: $65

Article Metrics

PDF: 38
HTML: 13